UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

	Kinase Fusion Gene Summary
	Kinase Fusion Gene Sample Information
	Kinase Fusion ORF Analysis
	Kinase Fusion Amino Acid Sequences
	Multiple Sequence Alignment of All Fusion Protein Isoforms
	Kinase Fusion Protein Functional Features
	Kinase Fusion Protein Structures
	Comparison of Fusion Protein Isoforms
	Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB
	pLDDT Scores and Difference Analysis of pLDDT Scores Between the Active Sites (Best) and Non-Active Sites.
	Ramachandran Plot of Kinase Fusion Protein Structure
	Potential Active Site Information
	Virtual Screening Results
	Kinase-Substrate Information
	Related Drugs with This Kinase Fusion Protein
	Related Disease with This Kinase Fusion Protein
	Clinical Trials of the Found Drugs/Small Molecules

Kinase Fusion Gene:CCDC6_RET

Kinase Fusion Protein Summary

Kinase Fusion gene summary

Kinase Fusion partner gene information	Kinase Fusion gene name: CCDC6_RET
	KinaseFusionDB ID: KFG958
	FusionGDB2.0 ID: KFG958
		Hgene	Tgene
	Gene symbol	CCDC6	RET
	Gene ID	8030	5979
	Gene name	coiled-coil domain containing 6	ret proto-oncogene
	Synonyms	D10S170\|H4\|PTC\|PTC1\|TPC\|TST1	CDHF12\|CDHR16\|HSCR1\|MEN2A\|MEN2B\|MTC1\|PTC\|RET-ELE1
	Cytomap	10q21.2	10q11.21
	Type of gene	protein-coding	protein-coding
	Description	coiled-coil domain-containing protein 6papillary thyroid carcinoma-encoded proteintransforming sequence, thyroid-1	proto-oncogene tyrosine-protein kinase receptor RetRET receptor tyrosine kinasecadherin family member 12cadherin-related family member 16proto-oncogene c-Retrearranged during transfectionret proto-oncogene (multiple endocrine neoplasia and medullary
	Modification date	20240305	20240416
	UniProtAcc	Q6ZP65	P07949
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000263102,	ENST00000340058, ENST00000355710,
Context (manual curation of fusion genes in KinaseFusionDB)	PubMed: CCDC6 [Title/Abstract] AND RET [Title/Abstract] AND fusion [Title/Abstract] RET, ROS1 and ALK fusions in lung cancer (pmid: 22327623)
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CCDC6(61665880)-RET(43612032), # samples:54 RET(43610184)-CCDC6(61612460), # samples:2

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	RET	GO:0030155	regulation of cell adhesion	21357690
Tgene	RET	GO:0030335	positive regulation of cell migration	20702524
Tgene	RET	GO:0033619	membrane protein proteolysis	21357690
Tgene	RET	GO:0033630	positive regulation of cell adhesion mediated by integrin	20702524
Tgene	RET	GO:0035860	glial cell-derived neurotrophic factor receptor signaling pathway	24560924\|25242331\|28953886\|31535977
Tgene	RET	GO:0043410	positive regulation of MAPK cascade	28846099

Kinase Fusion gene breakpoints across CCDC6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Kinase Fusion gene breakpoints across RET (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Kinase Fusion Gene Sample Information

Kinase Fusion gene information.

Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
ChimerDB4	TCGA-24-2298-01A	CCDC6	chr10	61665880	RET	chr10	43595907
ChimerDB4	TCGA-EL-A3ZP-01A	CCDC6	chr10	61665880	RET	chr10	43610035
ChimerKB3	.	CCDC6	chr10	61554230	RET	chr10	43609927
ChimerDB4	TCGA-CE-A13K-01A	CCDC6	chr10	61554231	RET	chr10	43612032
ChimerDB4	TCGA-CM-4743-01A	CCDC6	chr10	61665880	RET	chr10	43612032
ChimerDB4	TCGA-ET-A3DR	CCDC6	chr10	61665879	RET	chr10	43612031
ChimerKB3	.	CCDC6	chr10	61665879	RET	chr10	43612031
ChimerKB3	.	CCDC6	chr10	61665880	RET	chr10	43612031
ChimerKB3	.	CCDC6	chr10	61665880	RET	chr10	43612032
ChimerKB4	.	CCDC6	chr10	61665880	RET	chr10	43612031
ChiTaRS5.0	AB698668	CCDC6	chr10	61665879	RET	chr10	43612032
ChimerKB3	.	CCDC6	chr10	61665962	RET	chr10	43610127
ChimerKB3	.	CCDC6	chr10	61665962	RET	chr10	43612031
ChimerKB3	.	CCDC6	chr10	61666182	RET	chr10	43612031
ChimerKB3	.	CCDC6	chr10	61666182	RET	chr10	43612032
ChimerKB3	.	CCDC6	chr10	61666217	RET	chr10	43612031
ChimerKB3	.	CCDC6	chr10	61666217	RET	chr10	43612032
ChimerKB3	.	CCDC6	chr10	61666237	RET	chr10	43612032
ChiTaRS5.0	AF395885	CCDC6	chr10	61665030	RET	chr10	43610127
ChimerKB3	.	CCDC6	chr10	61335968	RET	chr10	42930132
ChimerKB3	.	CCDC6	chr10	61336223	RET	chr10	42932037
ChimerKB3	.	CCDC6	chr10	61336243	RET	chr10	42932037
COSMIC	2047069	CCDC6	chr10	61612311	RET	chr10	43612032
COSMIC	2047070	CCDC6	chr10	61612311	RET	chr10	43612032
COSMIC	2060471	CCDC6	chr10	61612311	RET	chr10	43612032
COSMIC	2060571	CCDC6	chr10	61553383	RET	chr10	43610053
COSMIC	2066314	CCDC6	chr10	61664769	RET	chr10	43611225
COSMIC	2066315	CCDC6	chr10	61664826	RET	chr10	43610185

Top

Kinase Fusion ORF Analysis

Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB.

Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Seq length (transcript)	Seq length (amino acids)
ENST00000263102	ENST00000355710	CCDC6	chr10	61612311	RET	chr10	43612032	3976	594
ENST00000263102	ENST00000355710	CCDC6	chr10	61665880	RET	chr10	43612032	3826	544
ENST00000263102	ENST00000355710	CCDC6	chr10	61554231	RET	chr10	43612032	4753	853
ENST00000263102	ENST00000355710	CCDC6	chr10	61665879	RET	chr10	43612031	3826	544
ENST00000263102	ENST00000355710	CCDC6	chr10	61665879	RET	chr10	43612032	3826	544
ENST00000263102	ENST00000355710	CCDC6	chr10	61665880	RET	chr10	43612031	3826	544

Top

Kinase Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq

>ENST00000263102_ENST00000355710_CCDC6_chr10_61612311_RET_chr10_43612032_length(amino acids)=594
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIQARAEQEEEFISNTLFKKIQALQKEKETLAVNYEKEEE
FLTNELSRKLMQEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKL
YGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNI
LVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRM
ERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENK

--------------------------------------------------------------

>ENST00000263102_ENST00000355710_CCDC6_chr10_61665880_RET_chr10_43612032_length(amino acids)=544
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA
GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH
PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT
QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA
STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD

--------------------------------------------------------------

>ENST00000263102_ENST00000355710_CCDC6_chr10_61554231_RET_chr10_43612032_length(amino acids)=853
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIQARAEQEEEFISNTLFKKIQALQKEKETLAVNYEKEEE
FLTNELSRKLMQLQHEKAELEQHLEQEQEFQVNKLMKKIKKLENDTISKQLTLEQLRREKIDLENTLEQEQEALVNRLWKRMDKLEAEKR
ILQEKLDQPVSAPPSPRDISMEIDSPENMMRHIRFLKNEVERLKKQLRAAQLQHSEKMAQYLEEERHMREENLRLQRKLQREMERREALC
RQLSESESSLEMDDERYFNEMSAQGLRPRTVSSPIPYTPSPSSSRPISPGLSYASHTVGFTPPTSLTRAGMSYYNSPGLHVQHMGTSHGI
TEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLL
LIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKIS
DFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMY
RLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPG

--------------------------------------------------------------

>ENST00000263102_ENST00000355710_CCDC6_chr10_61665879_RET_chr10_43612031_length(amino acids)=544
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA
GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH
PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT
QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA
STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD

--------------------------------------------------------------

>ENST00000263102_ENST00000355710_CCDC6_chr10_61665879_RET_chr10_43612032_length(amino acids)=544
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA
GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH
PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT
QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA
STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD

--------------------------------------------------------------

>ENST00000263102_ENST00000355710_CCDC6_chr10_61665880_RET_chr10_43612031_length(amino acids)=544
MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI
VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA
GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH
PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT
QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA
STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD

--------------------------------------------------------------

Multiple Sequence Alignment of All Fusion Protein Isoforms

Top

Kinase Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:61665880/chr10:43612032)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
CCDC6 Q6ZP65	RET P07949
FUNCTION: Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non-processive to a highly processive motor in the presence of dynactin. Facilitates the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track). Predominantly recruits 2 dyneins, which increases both the force and speed of the microtubule motor. Component of secretory vesicle machinery in developing neurons that acts as a regulator of neurite outgrowth. Regulates the secretory vesicle transport by controlling the accumulation of Rab6-containing secretory vesicles in the pericentrosomal region restricting anterograde secretory transport during the early phase of neuronal differentiation, thereby inhibiting neuritogenesis. {ECO:0000250\|UniProtKB:A0JNT9}.	FUNCTION: Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways (PubMed:28846097, PubMed:28953886, PubMed:28846099). Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL (PubMed:28846099). {ECO:0000269\|PubMed:20064382, ECO:0000269\|PubMed:20616503, ECO:0000269\|PubMed:20702524, ECO:0000269\|PubMed:21357690, ECO:0000269\|PubMed:21454698, ECO:0000269\|PubMed:28846097, ECO:0000269\|PubMed:28846099, ECO:0000269\|PubMed:28953886}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt).

Partner	Hgeneene	Hbp	Tgeneene	Tbp	ENST	BPexon	TotalExon	Protein feature loci	BPloci	TotalLen	Feature	Note
Tgene	CCDC6	61554231	RET	43612032	ENST00000263102	10	19	724_1016	712	1073	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61554231	RET	43612032	ENST00000263102	10	20	724_1016	712	1115	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61612311	RET	43612032	ENST00000263102	10	19	724_1016	712	1073	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61612311	RET	43612032	ENST00000263102	10	20	724_1016	712	1115	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665879	RET	43612031	ENST00000263102	10	19	724_1016	712	1073	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665879	RET	43612031	ENST00000263102	10	20	724_1016	712	1115	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665879	RET	43612032	ENST00000263102	10	19	724_1016	712	1073	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665879	RET	43612032	ENST00000263102	10	20	724_1016	712	1115	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665880	RET	43612031	ENST00000263102	10	19	724_1016	712	1073	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665880	RET	43612031	ENST00000263102	10	20	724_1016	712	1115	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665880	RET	43612032	ENST00000263102	10	19	724_1016	712	1073	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159
Tgene	CCDC6	61665880	RET	43612032	ENST00000263102	10	20	724_1016	712	1115	Domain	Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00159

Top

Kinase Fusion Protein Structures

CIF files of the predicted kinase fusion proteins
* Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format.

Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB)	Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	AA seq	Len(AA seq)
PDB file >>>88_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61665880	RET	chr10	43612031	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD	544
3D view using mol* of 88_CCDC6_RET

PDB file >>>TKFP_146_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61612311	RET	chr10	43612032	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIQARAEQEEEFISNTLFKKIQALQKEKETLAVNYEKEEE FLTNELSRKLMQEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKL YGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNI LVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRM ERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENK	594_CCDC6_RET
PDB file >>>TKFP_147_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61665880	RET	chr10	43612032	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD	544_CCDC6_RET
3D view using mol* of TKFP_147_CCDC6_RET

PDB file >>>TKFP_148_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61554231	RET	chr10	43612032	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIQARAEQEEEFISNTLFKKIQALQKEKETLAVNYEKEEE FLTNELSRKLMQLQHEKAELEQHLEQEQEFQVNKLMKKIKKLENDTISKQLTLEQLRREKIDLENTLEQEQEALVNRLWKRMDKLEAEKR ILQEKLDQPVSAPPSPRDISMEIDSPENMMRHIRFLKNEVERLKKQLRAAQLQHSEKMAQYLEEERHMREENLRLQRKLQREMERREALC RQLSESESSLEMDDERYFNEMSAQGLRPRTVSSPIPYTPSPSSSRPISPGLSYASHTVGFTPPTSLTRAGMSYYNSPGLHVQHMGTSHGI TEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLL LIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKIS DFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMY RLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPG	853_CCDC6_RET
3D view using mol* of TKFP_148_CCDC6_RET

PDB file >>>TKFP_149_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61665879	RET	chr10	43612031	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD	544_CCDC6_RET
PDB file >>>TKFP_150_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61665879	RET	chr10	43612032	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD	544_CCDC6_RET
PDB file >>>TKFP_151_CCDC6_RET	ENST00000263102	ENST00000355710	CCDC6	chr10	61665880	RET	chr10	43612031	MVPGAQLGAPLCSPGAHSFAARPSSPPPPCCSSSFPQPAAAMADSASESDTDGAGGNSSSSAAMQSSCSSTSGGGGGGGGGGGGGKSGGI VISPFRLEELTNRLASLQQENKVLKIELETYKLKCKALQEENRDLRKASVTIEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRA GYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTT QSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMD	544_CCDC6_RET

Top

Comparison of Fusion Protein Isoforms

Superimpose the 3D Structures Among All Fusion Protein Isoforms
* Download the pdb file and open it from the molstar online viewer.

3D view using mol* of viewer/superimpose_isoforms/TKFP_146_CCDC6_RET_vs_TKFP_147_CCDC6_RET_superimposed.pdb.html
3D view using mol* of viewer/superimpose_isoforms/TKFP_146_CCDC6_RET_vs_TKFP_148_CCDC6_RET_superimposed.pdb.html
3D view using mol* of viewer/superimpose_isoforms/TKFP_147_CCDC6_RET_vs_TKFP_148_CCDC6_RET_superimposed.pdb.html

Comparison of the Secondary Structures of Fusion Protein Isoforms

./secondary_str/TKFP_146_CCDC6_RET_vs_TKFP_147_CCDC6_RET.png

./secondary_str/TKFP_148_CCDC6_RET_vs_TKFP_146_CCDC6_RET.png

./secondary_str/TKFP_148_CCDC6_RET_vs_TKFP_147_CCDC6_RET.png

Top

Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB

Abstract of the Multiple Sequence Alignment of the Longest Fusion Protein Sequence and Known Sequence from PDB Search Using Fusion Gene Names

Multiple Sequence Alignment of the Longest Fusion Protein Sequence and Known Sequence from PDB Search Using Fusion Gene Names

Superimpose the 3D Structures Between the Longest Fusion Protein and the Longest Known PDB

3D view using mol* of viewer/superimpose_pdbs/CCDC6_RET_6FEK_superimposed.pdb.html
3D view using mol* of viewer/superimpose_pdbs/CCDC6_RET_7JU5_superimposed.pdb.html
3D view using mol* of viewer/superimpose_pdbs/CCDC6_RET_7JU6_superimposed.pdb.html
3D view using mol* of viewer/superimpose_pdbs/CCDC6_RET_7NZN_superimposed.pdb.html

Top

pLDDT score distribution

all_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/88_CCDC6_RET.pngall_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/TKFP_147_CCDC6_RET_updated_violin_plot.pngall_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/TKFP_148_CCDC6_RET_updated_violin_plot.png

pLDDT score distribution of the predicted fusion protein structures from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.
* The blue color at the bottom marks the best active site residues.

88_CCDC6_RET.png

TKFP_147_CCDC6_RET.png

TKFP_148_CCDC6_RET.png

Top

Potential Active Site Information

The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite.

Kinase Fusion AA seq ID in KinaseFusionDB	Site score	Size	Dscore	Volume	Exposure	Enclosure	Contact	Phobic	Philic	Balance	Don/Acc	Residues
TKFP_147_CCDC6_RET	1.023	232	1.004	703.15	0.545	0.733	0.953	0.598	1.153	0.518	0.575	Chain A: 138,141,163,164,165,191,195,197,198,200,2 01,203,204,207,243,247,250,303,304,306,308,309,322 ,325,327,335,336,337,338,339,341,342,343,344,345,3 46,347,373,378,379,380,381,383,384,387,529,530,531 ,532,533,535,536
TKFP_148_CCDC6_RET	1.087	110	1.132	281.603	0.502	0.764	0.976	1.218	0.818	1.489	1.618	Chain A: 469,470,471,472,473,474,475,477,495,497,5 14,518,527,541,543,544,545,546,549,550,617,618,620 ,630,631

Binding site residues of the found PDBs.

PDB accession	AA sequence	Residue position
6FEK	GLY	700
6FEK	PRO	701
6FEK	LEU	702
6FEK	SER	703
6FEK	LEU	704
6FEK	SER	705
6FEK	VAL	706
6FEK	ASP	707
6FEK	ALA	708
6FEK	PHE	709
6FEK	LYS	710
6FEK	ILE	711
6FEK	LEU	712
6FEK	ALA	713
6FEK	ALA	714
6FEK	PRO	715
6FEK	LYS	716
6FEK	TRP	717
6FEK	GLU	718
6FEK	PHE	719
6FEK	PRO	720
6FEK	ARG	721
6FEK	LYS	722
6FEK	ASN	723
6FEK	LEU	724
6FEK	VAL	725
6FEK	LEU	726
6FEK	GLY	727
6FEK	LYS	728
6FEK	THR	729
6FEK	LEU	730
6FEK	GLY	731
6FEK	GLU	732
6FEK	GLY	733
6FEK	GLU	734
6FEK	PHE	735
6FEK	GLY	736
6FEK	LYS	737
6FEK	VAL	738
6FEK	VAL	739
6FEK	LYS	740
6FEK	ALA	741
6FEK	THR	742
6FEK	ALA	743
6FEK	PHE	744
6FEK	HIS	745
6FEK	LEU	746
6FEK	LYS	747
6FEK	GLY	748
6FEK	ARG	749
6FEK	ALA	750
6FEK	GLY	751
6FEK	TYR	752
6FEK	THR	753
6FEK	THR	754
6FEK	VAL	755
6FEK	ALA	756
6FEK	VAL	757
6FEK	LYS	758
6FEK	MET	759
6FEK	LEU	760
6FEK	LYS	761
6FEK	GLU	762
6FEK	ASN	763
6FEK	ALA	764
6FEK	SER	765
6FEK	PRO	766
6FEK	SER	767
6FEK	GLU	768
6FEK	LEU	769
6FEK	ARG	770
6FEK	ASP	771
6FEK	LEU	772
6FEK	LEU	773
6FEK	SER	774
6FEK	GLU	775
6FEK	PHE	776
6FEK	ASN	777
6FEK	VAL	778
6FEK	LEU	779
6FEK	LYS	780
6FEK	GLN	781
6FEK	VAL	782
6FEK	ASN	783
6FEK	HIS	784
6FEK	PRO	785
6FEK	HIS	786
6FEK	VAL	787
6FEK	ILE	788
6FEK	LYS	789
6FEK	LEU	790
6FEK	TYR	791
6FEK	GLY	792
6FEK	ALA	793
6FEK	CYS	794
6FEK	SER	795
6FEK	GLN	796
6FEK	ASP	797
6FEK	GLY	798
6FEK	PRO	799
6FEK	LEU	800
6FEK	LEU	801
6FEK	LEU	802
6FEK	ILE	803
6FEK	VAL	804
6FEK	GLU	805
6FEK	TYR	806
6FEK	ALA	807
6FEK	LYS	808
6FEK	TYR	809
6FEK	GLY	810
6FEK	SER	811
6FEK	LEU	812
6FEK	ARG	813
6FEK	GLY	814
6FEK	PHE	815
6FEK	LEU	816
6FEK	ARG	817
6FEK	GLU	818
6FEK	SER	819
6FEK	ARG	820
6FEK	LYS	821
6FEK	VAL	822
6FEK	GLY	823
6FEK	PRO	824
6FEK	GLY	825
6FEK	PRO	841
6FEK	ASP	842
6FEK	GLU	843
6FEK	ARG	844
6FEK	ALA	845
6FEK	LEU	846
6FEK	THR	847
6FEK	MET	848
6FEK	GLY	849
6FEK	ASP	850
6FEK	LEU	851
6FEK	ILE	852
6FEK	SER	853
6FEK	PHE	854
6FEK	ALA	855
6FEK	TRP	856
6FEK	GLN	857
6FEK	ILE	858
6FEK	SER	859
6FEK	GLN	860
6FEK	GLY	861
6FEK	MET	862
6FEK	GLN	863
6FEK	TYR	864
6FEK	LEU	865
6FEK	ALA	866
6FEK	GLU	867
6FEK	MET	868
6FEK	LYS	869
6FEK	LEU	870
6FEK	VAL	871
6FEK	HIS	872
6FEK	ARG	873
6FEK	ASP	874
6FEK	LEU	875
6FEK	ALA	876
6FEK	ALA	877
6FEK	ARG	878
6FEK	ASN	879
6FEK	ILE	880
6FEK	LEU	881
6FEK	VAL	882
6FEK	ALA	883
6FEK	GLU	884
6FEK	GLY	885
6FEK	ARG	886
6FEK	LYS	887
6FEK	MET	888
6FEK	LYS	889
6FEK	ILE	890
6FEK	SER	891
6FEK	ASP	892
6FEK	PHE	893
6FEK	GLY	894
6FEK	LEU	895
6FEK	SER	896
6FEK	ARG	897
6FEK	ASP	898
6FEK	VAL	899
6FEK	GLU	901
6FEK	GLU	902
6FEK	ASP	903
6FEK	PHE	904
6FEK	VAL	906
6FEK	LYS	907
6FEK	ARG	908
6FEK	SER	909
6FEK	GLN	910
6FEK	GLY	911
6FEK	ARG	912
6FEK	ILE	913
6FEK	PRO	914
6FEK	VAL	915
6FEK	LYS	916
6FEK	TRP	917
6FEK	MET	918
6FEK	ALA	919
6FEK	ILE	920
6FEK	GLU	921
6FEK	SER	922
6FEK	LEU	923
6FEK	PHE	924
6FEK	ASP	925
6FEK	HIS	926
6FEK	ILE	927
6FEK	TYR	928
6FEK	THR	929
6FEK	THR	930
6FEK	GLN	931
6FEK	SER	932
6FEK	ASP	933
6FEK	VAL	934
6FEK	TRP	935
6FEK	SER	936
6FEK	PHE	937
6FEK	GLY	938
6FEK	VAL	939
6FEK	LEU	940
6FEK	LEU	941
6FEK	TRP	942
6FEK	GLU	943
6FEK	ILE	944
6FEK	VAL	945
6FEK	THR	946
6FEK	LEU	947
6FEK	GLY	948
6FEK	GLY	949
6FEK	ASN	950
6FEK	PRO	951
6FEK	TYR	952
6FEK	PRO	953
6FEK	GLY	954
6FEK	ILE	955
6FEK	PRO	956
6FEK	PRO	957
6FEK	GLU	958
6FEK	ARG	959
6FEK	LEU	960
6FEK	PHE	961
6FEK	ASN	962
6FEK	LEU	963
6FEK	LEU	964
6FEK	LYS	965
6FEK	THR	966
6FEK	GLY	967
6FEK	HIS	968
6FEK	ARG	969
6FEK	MET	970
6FEK	GLU	971
6FEK	ARG	972
6FEK	PRO	973
6FEK	ASP	974
6FEK	ASN	975
6FEK	CYS	976
6FEK	SER	977
6FEK	GLU	978
6FEK	GLU	979
6FEK	MET	980
6FEK	TYR	981
6FEK	ARG	982
6FEK	LEU	983
6FEK	MET	984
6FEK	LEU	985
6FEK	GLN	986
6FEK	CYS	987
6FEK	TRP	988
6FEK	LYS	989
6FEK	GLN	990
6FEK	GLU	991
6FEK	PRO	992
6FEK	ASP	993
6FEK	LYS	994
6FEK	ARG	995
6FEK	PRO	996
6FEK	VAL	997
6FEK	PHE	998
6FEK	ALA	999
6FEK	ASP	1000
6FEK	ILE	1001
6FEK	SER	1002
6FEK	LYS	1003
6FEK	ASP	1004
6FEK	LEU	1005
6FEK	GLU	1006
6FEK	LYS	1007
6FEK	MET	1008
6FEK	MET	1009
6FEK	VAL	1010
7JU5	GLY	700
7JU5	PRO	701
7JU5	LEU	702
7JU5	SER	703
7JU5	LEU	704
7JU5	SER	705
7JU5	VAL	706
7JU5	ASP	707
7JU5	ALA	708
7JU5	PHE	709
7JU5	LYS	710
7JU5	ILE	711
7JU5	LEU	712
7JU5	GLU	713
7JU5	ASP	714
7JU5	PRO	715
7JU5	LYS	716
7JU5	TRP	717
7JU5	GLU	718
7JU5	PHE	719
7JU5	PRO	720
7JU5	ARG	721
7JU5	LYS	722
7JU5	ASN	723
7JU5	LEU	724
7JU5	VAL	725
7JU5	LEU	726
7JU5	GLY	727
7JU5	LYS	728
7JU5	THR	729
7JU5	LEU	730
7JU5	GLY	731
7JU5	GLU	732
7JU5	GLY	733
7JU5	GLU	734
7JU5	PHE	735
7JU5	GLY	736
7JU5	LYS	737
7JU5	VAL	738
7JU5	VAL	739
7JU5	LYS	740
7JU5	ALA	741
7JU5	THR	742
7JU5	ALA	743
7JU5	PHE	744
7JU5	HIS	745
7JU5	LEU	746
7JU5	LYS	747
7JU5	GLY	748
7JU5	ARG	749
7JU5	ALA	750
7JU5	GLY	751
7JU5	TYR	752
7JU5	THR	753
7JU5	THR	754
7JU5	VAL	755
7JU5	ALA	756
7JU5	VAL	757
7JU5	LYS	758
7JU5	MET	759
7JU5	LEU	760
7JU5	LYS	761
7JU5	GLU	762
7JU5	ASN	763
7JU5	ALA	764
7JU5	SER	765
7JU5	PRO	766
7JU5	SER	767
7JU5	GLU	768
7JU5	LEU	769
7JU5	ARG	770
7JU5	ASP	771
7JU5	LEU	772
7JU5	LEU	773
7JU5	SER	774
7JU5	GLU	775
7JU5	PHE	776
7JU5	ASN	777
7JU5	VAL	778
7JU5	LEU	779
7JU5	LYS	780
7JU5	GLN	781
7JU5	VAL	782
7JU5	ASN	783
7JU5	HIS	784
7JU5	PRO	785
7JU5	HIS	786
7JU5	VAL	787
7JU5	ILE	788
7JU5	LYS	789
7JU5	LEU	790
7JU5	TYR	791
7JU5	GLY	792
7JU5	ALA	793
7JU5	CYS	794
7JU5	SER	795
7JU5	GLN	796
7JU5	ASP	797
7JU5	GLY	798
7JU5	PRO	799
7JU5	LEU	800
7JU5	LEU	801
7JU5	LEU	802
7JU5	ILE	803
7JU5	VAL	804
7JU5	GLU	805
7JU5	TYR	806
7JU5	ALA	807
7JU5	LYS	808
7JU5	TYR	809
7JU5	GLY	810
7JU5	SER	811
7JU5	LEU	812
7JU5	ARG	813
7JU5	GLY	814
7JU5	PHE	815
7JU5	LEU	816
7JU5	ARG	817
7JU5	GLU	818
7JU5	SER	819
7JU5	ARG	820
7JU5	LYS	821
7JU5	VAL	822
7JU5	GLY	823
7JU5	GLU	843
7JU5	ARG	844
7JU5	ALA	845
7JU5	LEU	846
7JU5	THR	847
7JU5	MET	848
7JU5	GLY	849
7JU5	ASP	850
7JU5	LEU	851
7JU5	ILE	852
7JU5	SER	853
7JU5	PHE	854
7JU5	ALA	855
7JU5	TRP	856
7JU5	GLN	857
7JU5	ILE	858
7JU5	SER	859
7JU5	GLN	860
7JU5	GLY	861
7JU5	MET	862
7JU5	GLN	863
7JU5	TYR	864
7JU5	LEU	865
7JU5	ALA	866
7JU5	GLU	867
7JU5	MET	868
7JU5	LYS	869
7JU5	LEU	870
7JU5	VAL	871
7JU5	HIS	872
7JU5	ARG	873
7JU5	ASP	874
7JU5	LEU	875
7JU5	ALA	876
7JU5	ALA	877
7JU5	ARG	878
7JU5	ASN	879
7JU5	ILE	880
7JU5	LEU	881
7JU5	VAL	882
7JU5	ALA	883
7JU5	GLU	884
7JU5	GLY	885
7JU5	ARG	886
7JU5	LYS	887
7JU5	MET	888
7JU5	LYS	889
7JU5	ILE	890
7JU5	SER	891
7JU5	ASP	892
7JU5	PHE	893
7JU5	GLY	894
7JU5	LEU	895
7JU5	SER	896
7JU5	ARG	897
7JU5	ASP	898
7JU5	VAL	899
7JU5	TYR	900
7JU5	SER	909
7JU5	GLN	910
7JU5	GLY	911
7JU5	ARG	912
7JU5	ILE	913
7JU5	PRO	914
7JU5	VAL	915
7JU5	LYS	916
7JU5	TRP	917
7JU5	MET	918
7JU5	ALA	919
7JU5	ILE	920
7JU5	GLU	921
7JU5	SER	922
7JU5	LEU	923
7JU5	PHE	924
7JU5	ASP	925
7JU5	HIS	926
7JU5	ILE	927
7JU5	TYR	928
7JU5	THR	929
7JU5	THR	930
7JU5	GLN	931
7JU5	SER	932
7JU5	ASP	933
7JU5	VAL	934
7JU5	TRP	935
7JU5	SER	936
7JU5	PHE	937
7JU5	GLY	938
7JU5	VAL	939
7JU5	LEU	940
7JU5	LEU	941
7JU5	TRP	942
7JU5	GLU	943
7JU5	ILE	944
7JU5	VAL	945
7JU5	THR	946
7JU5	LEU	947
7JU5	GLY	948
7JU5	GLY	949
7JU5	ASN	950
7JU5	PRO	951
7JU5	TYR	952
7JU5	PRO	953
7JU5	GLY	954
7JU5	ILE	955
7JU5	PRO	956
7JU5	PRO	957
7JU5	GLU	958
7JU5	ARG	959
7JU5	LEU	960
7JU5	PHE	961
7JU5	ASN	962
7JU5	LEU	963
7JU5	LEU	964
7JU5	LYS	965
7JU5	THR	966
7JU5	GLY	967
7JU5	HIS	968
7JU5	ARG	969
7JU5	MET	970
7JU5	GLU	971
7JU5	ARG	972
7JU5	PRO	973
7JU5	ASP	974
7JU5	ASN	975
7JU5	CYS	976
7JU5	SER	977
7JU5	GLU	978
7JU5	GLU	979
7JU5	MET	980
7JU5	TYR	981
7JU5	ARG	982
7JU5	LEU	983
7JU5	MET	984
7JU5	LEU	985
7JU5	GLN	986
7JU5	CYS	987
7JU5	TRP	988
7JU5	LYS	989
7JU5	GLN	990
7JU5	GLU	991
7JU5	PRO	992
7JU5	ASP	993
7JU5	LYS	994
7JU5	ARG	995
7JU5	PRO	996
7JU5	VAL	997
7JU5	PHE	998
7JU5	ALA	999
7JU5	ASP	1000
7JU5	ILE	1001
7JU5	SER	1002
7JU5	LYS	1003
7JU5	ASP	1004
7JU5	LEU	1005
7JU5	GLU	1006
7JU5	LYS	1007
7JU5	MET	1008
7JU5	MET	1009
7JU5	VAL	1010
7JU5	LYS	1011
7JU5	ARG	1012
7JU5	ARG	1013
7JU5	LYS	710
7JU5	ILE	711
7JU5	LEU	712
7JU5	GLU	713
7JU5	ASP	714
7JU5	PRO	715
7JU5	LYS	716
7JU5	TRP	717
7JU5	GLU	718
7JU5	PHE	719
7JU5	PRO	720
7JU5	ARG	721
7JU5	LYS	722
7JU5	ASN	723
7JU5	LEU	724
7JU5	VAL	725
7JU5	LEU	726
7JU5	GLY	727
7JU5	LYS	728
7JU5	THR	729
7JU5	LEU	730
7JU5	GLY	731
7JU5	GLU	732
7JU5	GLY	733
7JU5	GLU	734
7JU5	PHE	735
7JU5	GLY	736
7JU5	LYS	737
7JU5	VAL	738
7JU5	VAL	739
7JU5	LYS	740
7JU5	ALA	741
7JU5	THR	742
7JU5	ALA	743
7JU5	PHE	744
7JU5	HIS	745
7JU5	LEU	746
7JU5	LYS	747
7JU5	GLY	748
7JU5	ARG	749
7JU5	ALA	750
7JU5	GLY	751
7JU5	TYR	752
7JU5	THR	753
7JU5	THR	754
7JU5	VAL	755
7JU5	ALA	756
7JU5	VAL	757
7JU5	LYS	758
7JU5	MET	759
7JU5	LEU	760
7JU5	LYS	761
7JU5	GLU	762
7JU5	ASN	763
7JU5	ALA	764
7JU5	SER	765
7JU5	PRO	766
7JU5	SER	767
7JU5	GLU	768
7JU5	LEU	769
7JU5	ARG	770
7JU5	ASP	771
7JU5	LEU	772
7JU5	LEU	773
7JU5	SER	774
7JU5	GLU	775
7JU5	PHE	776
7JU5	ASN	777
7JU5	VAL	778
7JU5	LEU	779
7JU5	LYS	780
7JU5	GLN	781
7JU5	VAL	782
7JU5	ASN	783
7JU5	HIS	784
7JU5	PRO	785
7JU5	HIS	786
7JU5	VAL	787
7JU5	ILE	788
7JU5	LYS	789
7JU5	LEU	790
7JU5	TYR	791
7JU5	GLY	792
7JU5	ALA	793
7JU5	CYS	794
7JU5	SER	795
7JU5	GLN	796
7JU5	ASP	797
7JU5	GLY	798
7JU5	PRO	799
7JU5	LEU	800
7JU5	LEU	801
7JU5	LEU	802
7JU5	ILE	803
7JU5	VAL	804
7JU5	GLU	805
7JU5	TYR	806
7JU5	ALA	807
7JU5	LYS	808
7JU5	TYR	809
7JU5	GLY	810
7JU5	SER	811
7JU5	LEU	812
7JU5	ARG	813
7JU5	GLY	814
7JU5	PHE	815
7JU5	LEU	816
7JU5	ARG	817
7JU5	GLU	818
7JU5	SER	819
7JU5	ARG	820
7JU5	LYS	821
7JU5	VAL	822
7JU5	GLY	823
7JU5	PRO	824
7JU5	GLY	825
7JU5	TYR	826
7JU5	LEU	827
7JU5	GLY	828
7JU5	ASP	842
7JU5	GLU	843
7JU5	ARG	844
7JU5	ALA	845
7JU5	LEU	846
7JU5	THR	847
7JU5	MET	848
7JU5	GLY	849
7JU5	ASP	850
7JU5	LEU	851
7JU5	ILE	852
7JU5	SER	853
7JU5	PHE	854
7JU5	ALA	855
7JU5	TRP	856
7JU5	GLN	857
7JU5	ILE	858
7JU5	SER	859
7JU5	GLN	860
7JU5	GLY	861
7JU5	MET	862
7JU5	GLN	863
7JU5	TYR	864
7JU5	LEU	865
7JU5	ALA	866
7JU5	GLU	867
7JU5	MET	868
7JU5	LYS	869
7JU5	LEU	870
7JU5	VAL	871
7JU5	HIS	872
7JU5	ARG	873
7JU5	ASP	874
7JU5	LEU	875
7JU5	ALA	876
7JU5	ALA	877
7JU5	ARG	878
7JU5	ASN	879
7JU5	ILE	880
7JU5	LEU	881
7JU5	VAL	882
7JU5	ALA	883
7JU5	GLU	884
7JU5	GLY	885
7JU5	ARG	886
7JU5	LYS	887
7JU5	MET	888
7JU5	LYS	889
7JU5	ILE	890
7JU5	SER	891
7JU5	ASP	892
7JU5	PHE	893
7JU5	GLY	894
7JU5	LEU	895
7JU5	SER	896
7JU5	ARG	897
7JU5	ASP	898
7JU5	VAL	899
7JU5	TYR	900
7JU5	GLU	901
7JU5	GLU	902
7JU5	ASP	903
7JU5	SER	904
7JU5	TYR	905
7JU5	VAL	906
7JU5	LYS	907
7JU5	ARG	908
7JU5	SER	909
7JU5	GLN	910
7JU5	GLY	911
7JU5	ARG	912
7JU5	ILE	913
7JU5	PRO	914
7JU5	VAL	915
7JU5	LYS	916
7JU5	TRP	917
7JU5	MET	918
7JU5	ALA	919
7JU5	ILE	920
7JU5	GLU	921
7JU5	SER	922
7JU5	LEU	923
7JU5	PHE	924
7JU5	ASP	925
7JU5	HIS	926
7JU5	ILE	927
7JU5	TYR	928
7JU5	THR	929
7JU5	THR	930
7JU5	GLN	931
7JU5	SER	932
7JU5	ASP	933
7JU5	VAL	934
7JU5	TRP	935
7JU5	SER	936
7JU5	PHE	937
7JU5	GLY	938
7JU5	VAL	939
7JU5	LEU	940
7JU5	LEU	941
7JU5	TRP	942
7JU5	GLU	943
7JU5	ILE	944
7JU5	VAL	945
7JU5	THR	946
7JU5	LEU	947
7JU5	GLY	948
7JU5	GLY	949
7JU5	ASN	950
7JU5	PRO	951
7JU5	TYR	952
7JU5	PRO	953
7JU5	GLY	954
7JU5	ILE	955
7JU5	PRO	956
7JU5	PRO	957
7JU5	GLU	958
7JU5	ARG	959
7JU5	LEU	960
7JU5	PHE	961
7JU5	ASN	962
7JU5	LEU	963
7JU5	LEU	964
7JU5	LYS	965
7JU5	THR	966
7JU5	GLY	967
7JU5	HIS	968
7JU5	ARG	969
7JU5	MET	970
7JU5	GLU	971
7JU5	ARG	972
7JU5	PRO	973
7JU5	ASP	974
7JU5	ASN	975
7JU5	CYS	976
7JU5	SER	977
7JU5	GLU	978
7JU5	GLU	979
7JU5	MET	980
7JU5	TYR	981
7JU5	ARG	982
7JU5	LEU	983
7JU5	MET	984
7JU5	LEU	985
7JU5	GLN	986
7JU5	CYS	987
7JU5	TRP	988
7JU5	LYS	989
7JU5	GLN	990
7JU5	GLU	991
7JU5	PRO	992
7JU5	ASP	993
7JU5	LYS	994
7JU5	ARG	995
7JU5	PRO	996
7JU5	VAL	997
7JU5	PHE	998
7JU5	ALA	999
7JU5	ASP	1000
7JU5	ILE	1001
7JU5	SER	1002
7JU5	LYS	1003
7JU5	ASP	1004
7JU5	LEU	1005
7JU5	GLU	1006
7JU5	LYS	1007
7JU5	MET	1008
7JU5	MET	1009
7JU5	VAL	1010
7JU5	LYS	1011
7JU5	ARG	1012
7JU6	GLU	713
7JU6	ASP	714
7JU6	PRO	715
7JU6	LYS	716
7JU6	TRP	717
7JU6	GLU	718
7JU6	PHE	719
7JU6	PRO	720
7JU6	ARG	721
7JU6	LYS	722
7JU6	ASN	723
7JU6	LEU	724
7JU6	VAL	725
7JU6	LEU	726
7JU6	GLY	727
7JU6	LYS	728
7JU6	THR	729
7JU6	LEU	730
7JU6	GLY	731
7JU6	GLU	732
7JU6	GLY	733
7JU6	GLU	734
7JU6	PHE	735
7JU6	GLY	736
7JU6	LYS	737
7JU6	VAL	738
7JU6	VAL	739
7JU6	LYS	740
7JU6	ALA	741
7JU6	THR	742
7JU6	ALA	743
7JU6	PHE	744
7JU6	HIS	745
7JU6	LEU	746
7JU6	LYS	747
7JU6	GLY	748
7JU6	ARG	749
7JU6	ALA	750
7JU6	GLY	751
7JU6	TYR	752
7JU6	THR	753
7JU6	THR	754
7JU6	VAL	755
7JU6	ALA	756
7JU6	VAL	757
7JU6	LYS	758
7JU6	MET	759
7JU6	LEU	760
7JU6	LYS	761
7JU6	GLU	762
7JU6	ASN	763
7JU6	ALA	764
7JU6	SER	765
7JU6	PRO	766
7JU6	SER	767
7JU6	GLU	768
7JU6	LEU	769
7JU6	ARG	770
7JU6	ASP	771
7JU6	LEU	772
7JU6	LEU	773
7JU6	SER	774
7JU6	GLU	775
7JU6	PHE	776
7JU6	ASN	777
7JU6	VAL	778
7JU6	LEU	779
7JU6	LYS	780
7JU6	GLN	781
7JU6	VAL	782
7JU6	ASN	783
7JU6	HIS	784
7JU6	PRO	785
7JU6	HIS	786
7JU6	VAL	787
7JU6	ILE	788
7JU6	LYS	789
7JU6	LEU	790
7JU6	TYR	791
7JU6	GLY	792
7JU6	ALA	793
7JU6	CYS	794
7JU6	SER	795
7JU6	GLN	796
7JU6	ASP	797
7JU6	GLY	798
7JU6	PRO	799
7JU6	LEU	800
7JU6	LEU	801
7JU6	LEU	802
7JU6	ILE	803
7JU6	VAL	804
7JU6	GLU	805
7JU6	TYR	806
7JU6	ALA	807
7JU6	LYS	808
7JU6	TYR	809
7JU6	GLY	810
7JU6	SER	811
7JU6	LEU	812
7JU6	ARG	813
7JU6	GLY	814
7JU6	PHE	815
7JU6	LEU	816
7JU6	ARG	817
7JU6	GLU	818
7JU6	SER	819
7JU6	ARG	820
7JU6	LYS	821
7JU6	VAL	822
7JU6	GLY	823
7JU6	PRO	824
7JU6	GLY	825
7JU6	TYR	826
7JU6	LEU	827
7JU6	GLY	828
7JU6	PRO	841
7JU6	ASP	842
7JU6	GLU	843
7JU6	ARG	844
7JU6	ALA	845
7JU6	LEU	846
7JU6	THR	847
7JU6	MET	848
7JU6	GLY	849
7JU6	ASP	850
7JU6	LEU	851
7JU6	ILE	852
7JU6	SER	853
7JU6	PHE	854
7JU6	ALA	855
7JU6	TRP	856
7JU6	GLN	857
7JU6	ILE	858
7JU6	SER	859
7JU6	GLN	860
7JU6	GLY	861
7JU6	MET	862
7JU6	GLN	863
7JU6	TYR	864
7JU6	LEU	865
7JU6	ALA	866
7JU6	GLU	867
7JU6	MET	868
7JU6	LYS	869
7JU6	LEU	870
7JU6	VAL	871
7JU6	HIS	872
7JU6	ARG	873
7JU6	ASP	874
7JU6	LEU	875
7JU6	ALA	876
7JU6	ALA	877
7JU6	ARG	878
7JU6	ASN	879
7JU6	ILE	880
7JU6	LEU	881
7JU6	VAL	882
7JU6	ALA	883
7JU6	GLU	884
7JU6	GLY	885
7JU6	ARG	886
7JU6	LYS	887
7JU6	MET	888
7JU6	LYS	889
7JU6	ILE	890
7JU6	SER	891
7JU6	ASP	892
7JU6	PHE	893
7JU6	GLY	894
7JU6	LEU	895
7JU6	SER	896
7JU6	ARG	897
7JU6	ASP	898
7JU6	VAL	899
7JU6	TYR	900
7JU6	GLU	901
7JU6	GLU	902
7JU6	ASP	903
7JU6	SER	904
7JU6	TYR	905
7JU6	VAL	906
7JU6	LYS	907
7JU6	ARG	908
7JU6	SER	909
7JU6	GLN	910
7JU6	GLY	911
7JU6	ARG	912
7JU6	ILE	913
7JU6	PRO	914
7JU6	VAL	915
7JU6	LYS	916
7JU6	TRP	917
7JU6	MET	918
7JU6	ALA	919
7JU6	ILE	920
7JU6	GLU	921
7JU6	SER	922
7JU6	LEU	923
7JU6	PHE	924
7JU6	ASP	925
7JU6	HIS	926
7JU6	ILE	927
7JU6	TYR	928
7JU6	THR	929
7JU6	THR	930
7JU6	GLN	931
7JU6	SER	932
7JU6	ASP	933
7JU6	VAL	934
7JU6	TRP	935
7JU6	SER	936
7JU6	PHE	937
7JU6	GLY	938
7JU6	VAL	939
7JU6	LEU	940
7JU6	LEU	941
7JU6	TRP	942
7JU6	GLU	943
7JU6	ILE	944
7JU6	VAL	945
7JU6	THR	946
7JU6	LEU	947
7JU6	GLY	948
7JU6	GLY	949
7JU6	ASN	950
7JU6	PRO	951
7JU6	TYR	952
7JU6	PRO	953
7JU6	GLY	954
7JU6	ILE	955
7JU6	PRO	956
7JU6	PRO	957
7JU6	GLU	958
7JU6	ARG	959
7JU6	LEU	960
7JU6	PHE	961
7JU6	ASN	962
7JU6	LEU	963
7JU6	LEU	964
7JU6	LYS	965
7JU6	THR	966
7JU6	GLY	967
7JU6	HIS	968
7JU6	ARG	969
7JU6	MET	970
7JU6	GLU	971
7JU6	ARG	972
7JU6	PRO	973
7JU6	ASP	974
7JU6	ASN	975
7JU6	CYS	976
7JU6	SER	977
7JU6	GLU	978
7JU6	GLU	979
7JU6	MET	980
7JU6	TYR	981
7JU6	ARG	982
7JU6	LEU	983
7JU6	MET	984
7JU6	LEU	985
7JU6	GLN	986
7JU6	CYS	987
7JU6	TRP	988
7JU6	LYS	989
7JU6	GLN	990
7JU6	GLU	991
7JU6	PRO	992
7JU6	ASP	993
7JU6	LYS	994
7JU6	ARG	995
7JU6	PRO	996
7JU6	VAL	997
7JU6	PHE	998
7JU6	ALA	999
7JU6	ASP	1000
7JU6	ILE	1001
7JU6	SER	1002
7JU6	LYS	1003
7JU6	ASP	1004
7JU6	LEU	1005
7JU6	GLU	1006
7JU6	LYS	1007
7JU6	MET	1008
7JU6	MET	1009
7JU6	VAL	1010
7JU6	LYS	1011
7JU6	ARG	1012
7JU6	GLY	700
7JU6	PRO	701
7JU6	LEU	702
7JU6	SER	703
7JU6	LEU	704
7JU6	SER	705
7JU6	VAL	706
7JU6	ASP	707
7JU6	ALA	708
7JU6	PHE	709
7JU6	LYS	710
7JU6	ILE	711
7JU6	LEU	712
7JU6	GLU	713
7JU6	ASP	714
7JU6	PRO	715
7JU6	LYS	716
7JU6	TRP	717
7JU6	GLU	718
7JU6	PHE	719
7JU6	PRO	720
7JU6	ARG	721
7JU6	LYS	722
7JU6	ASN	723
7JU6	LEU	724
7JU6	VAL	725
7JU6	LEU	726
7JU6	GLY	727
7JU6	LYS	728
7JU6	THR	729
7JU6	LEU	730
7JU6	GLY	731
7JU6	GLU	732
7JU6	GLY	733
7JU6	GLU	734
7JU6	PHE	735
7JU6	GLY	736
7JU6	LYS	737
7JU6	VAL	738
7JU6	VAL	739
7JU6	LYS	740
7JU6	ALA	741
7JU6	THR	742
7JU6	ALA	743
7JU6	PHE	744
7JU6	HIS	745
7JU6	LEU	746
7JU6	LYS	747
7JU6	GLY	748
7JU6	ARG	749
7JU6	ALA	750
7JU6	GLY	751
7JU6	TYR	752
7JU6	THR	753
7JU6	THR	754
7JU6	VAL	755
7JU6	ALA	756
7JU6	VAL	757
7JU6	LYS	758
7JU6	MET	759
7JU6	LEU	760
7JU6	LYS	761
7JU6	GLU	762
7JU6	ASN	763
7JU6	ALA	764
7JU6	SER	765
7JU6	PRO	766
7JU6	SER	767
7JU6	GLU	768
7JU6	LEU	769
7JU6	ARG	770
7JU6	ASP	771
7JU6	LEU	772
7JU6	LEU	773
7JU6	SER	774
7JU6	GLU	775
7JU6	PHE	776
7JU6	ASN	777
7JU6	VAL	778
7JU6	LEU	779
7JU6	LYS	780
7JU6	GLN	781
7JU6	VAL	782
7JU6	ASN	783
7JU6	HIS	784
7JU6	PRO	785
7JU6	HIS	786
7JU6	VAL	787
7JU6	ILE	788
7JU6	LYS	789
7JU6	LEU	790
7JU6	TYR	791
7JU6	GLY	792
7JU6	ALA	793
7JU6	CYS	794
7JU6	SER	795
7JU6	GLN	796
7JU6	ASP	797
7JU6	GLY	798
7JU6	PRO	799
7JU6	LEU	800
7JU6	LEU	801
7JU6	LEU	802
7JU6	ILE	803
7JU6	VAL	804
7JU6	GLU	805
7JU6	TYR	806
7JU6	ALA	807
7JU6	LYS	808
7JU6	TYR	809
7JU6	GLY	810
7JU6	SER	811
7JU6	LEU	812
7JU6	ARG	813
7JU6	GLY	814
7JU6	PHE	815
7JU6	LEU	816
7JU6	ARG	817
7JU6	GLU	818
7JU6	SER	819
7JU6	ARG	820
7JU6	LYS	821
7JU6	VAL	822
7JU6	GLY	823
7JU6	SER	837
7JU6	LEU	838
7JU6	ASP	839
7JU6	HIS	840
7JU6	PRO	841
7JU6	ASP	842
7JU6	GLU	843
7JU6	ARG	844
7JU6	ALA	845
7JU6	LEU	846
7JU6	THR	847
7JU6	MET	848
7JU6	GLY	849
7JU6	ASP	850
7JU6	LEU	851
7JU6	ILE	852
7JU6	SER	853
7JU6	PHE	854
7JU6	ALA	855
7JU6	TRP	856
7JU6	GLN	857
7JU6	ILE	858
7JU6	SER	859
7JU6	GLN	860
7JU6	GLY	861
7JU6	MET	862
7JU6	GLN	863
7JU6	TYR	864
7JU6	LEU	865
7JU6	ALA	866
7JU6	GLU	867
7JU6	MET	868
7JU6	LYS	869
7JU6	LEU	870
7JU6	VAL	871
7JU6	HIS	872
7JU6	ARG	873
7JU6	ASP	874
7JU6	LEU	875
7JU6	ALA	876
7JU6	ALA	877
7JU6	ARG	878
7JU6	ASN	879
7JU6	ILE	880
7JU6	LEU	881
7JU6	VAL	882
7JU6	ALA	883
7JU6	GLU	884
7JU6	GLY	885
7JU6	ARG	886
7JU6	LYS	887
7JU6	MET	888
7JU6	LYS	889
7JU6	ILE	890
7JU6	SER	891
7JU6	ASP	892
7JU6	PHE	893
7JU6	GLY	894
7JU6	LEU	895
7JU6	SER	896
7JU6	ARG	897
7JU6	ASP	898
7JU6	VAL	899
7JU6	SER	909
7JU6	GLN	910
7JU6	GLY	911
7JU6	ARG	912
7JU6	ILE	913
7JU6	PRO	914
7JU6	VAL	915
7JU6	LYS	916
7JU6	TRP	917
7JU6	MET	918
7JU6	ALA	919
7JU6	ILE	920
7JU6	GLU	921
7JU6	SER	922
7JU6	LEU	923
7JU6	PHE	924
7JU6	ASP	925
7JU6	HIS	926
7JU6	ILE	927
7JU6	TYR	928
7JU6	THR	929
7JU6	THR	930
7JU6	GLN	931
7JU6	SER	932
7JU6	ASP	933
7JU6	VAL	934
7JU6	TRP	935
7JU6	SER	936
7JU6	PHE	937
7JU6	GLY	938
7JU6	VAL	939
7JU6	LEU	940
7JU6	LEU	941
7JU6	TRP	942
7JU6	GLU	943
7JU6	ILE	944
7JU6	VAL	945
7JU6	THR	946
7JU6	LEU	947
7JU6	GLY	948
7JU6	GLY	949
7JU6	ASN	950
7JU6	PRO	951
7JU6	TYR	952
7JU6	PRO	953
7JU6	GLY	954
7JU6	ILE	955
7JU6	PRO	956
7JU6	PRO	957
7JU6	GLU	958
7JU6	ARG	959
7JU6	LEU	960
7JU6	PHE	961
7JU6	ASN	962
7JU6	LEU	963
7JU6	LEU	964
7JU6	LYS	965
7JU6	THR	966
7JU6	GLY	967
7JU6	HIS	968
7JU6	ARG	969
7JU6	MET	970
7JU6	GLU	971
7JU6	ARG	972
7JU6	PRO	973
7JU6	ASP	974
7JU6	ASN	975
7JU6	CYS	976
7JU6	SER	977
7JU6	GLU	978
7JU6	GLU	979
7JU6	MET	980
7JU6	TYR	981
7JU6	ARG	982
7JU6	LEU	983
7JU6	MET	984
7JU6	LEU	985
7JU6	GLN	986
7JU6	CYS	987
7JU6	TRP	988
7JU6	LYS	989
7JU6	GLN	990
7JU6	GLU	991
7JU6	PRO	992
7JU6	ASP	993
7JU6	LYS	994
7JU6	ARG	995
7JU6	PRO	996
7JU6	VAL	997
7JU6	PHE	998
7JU6	ALA	999
7JU6	ASP	1000
7JU6	ILE	1001
7JU6	SER	1002
7JU6	LYS	1003
7JU6	ASP	1004
7JU6	LEU	1005
7JU6	GLU	1006
7JU6	LYS	1007
7JU6	MET	1008
7JU6	MET	1009
7JU6	VAL	1010
7JU6	LYS	1011
7JU6	ARG	1012
7NZN	GLY	700
7NZN	PRO	701
7NZN	LEU	702
7NZN	SER	703
7NZN	LEU	704
7NZN	SER	705
7NZN	VAL	706
7NZN	ASP	707
7NZN	ALA	708
7NZN	PHE	709
7NZN	LYS	710
7NZN	ILE	711
7NZN	ASP	714
7NZN	PRO	715
7NZN	LYS	716
7NZN	TRP	717
7NZN	GLU	718
7NZN	PHE	719
7NZN	PRO	720
7NZN	ARG	721
7NZN	LYS	722
7NZN	ASN	723
7NZN	LEU	724
7NZN	VAL	725
7NZN	LEU	726
7NZN	GLY	727
7NZN	LYS	728
7NZN	THR	729
7NZN	LEU	730
7NZN	GLY	731
7NZN	GLU	732
7NZN	GLY	733
7NZN	GLU	734
7NZN	PHE	735
7NZN	GLY	736
7NZN	LYS	737
7NZN	VAL	738
7NZN	VAL	739
7NZN	LYS	740
7NZN	ALA	741
7NZN	THR	742
7NZN	ALA	743
7NZN	PHE	744
7NZN	HIS	745
7NZN	LEU	746
7NZN	LYS	747
7NZN	GLY	748
7NZN	ARG	749
7NZN	ALA	750
7NZN	GLY	751
7NZN	TYR	752
7NZN	THR	753
7NZN	THR	754
7NZN	VAL	755
7NZN	ALA	756
7NZN	VAL	757
7NZN	LYS	758
7NZN	MET	759
7NZN	LEU	760
7NZN	LYS	761
7NZN	GLU	762
7NZN	ASN	763
7NZN	ALA	764
7NZN	SER	765
7NZN	PRO	766
7NZN	SER	767
7NZN	GLU	768
7NZN	LEU	769
7NZN	ARG	770
7NZN	ASP	771
7NZN	LEU	772
7NZN	LEU	773
7NZN	SER	774
7NZN	GLU	775
7NZN	PHE	776
7NZN	ASN	777
7NZN	VAL	778
7NZN	LEU	779
7NZN	LYS	780
7NZN	GLN	781
7NZN	VAL	782
7NZN	ASN	783
7NZN	HIS	784
7NZN	PRO	785
7NZN	HIS	786
7NZN	VAL	787
7NZN	ILE	788
7NZN	LYS	789
7NZN	LEU	790
7NZN	TYR	791
7NZN	GLY	792
7NZN	ALA	793
7NZN	CYS	794
7NZN	SER	795
7NZN	GLN	796
7NZN	ASP	797
7NZN	GLY	798
7NZN	PRO	799
7NZN	LEU	800
7NZN	LEU	801
7NZN	LEU	802
7NZN	ILE	803
7NZN	VAL	804
7NZN	GLU	805
7NZN	TYR	806
7NZN	ALA	807
7NZN	LYS	808
7NZN	TYR	809
7NZN	GLY	810
7NZN	SER	811
7NZN	LEU	812
7NZN	ARG	813
7NZN	GLY	814
7NZN	PHE	815
7NZN	LEU	816
7NZN	ARG	817
7NZN	GLU	818
7NZN	SER	819
7NZN	ARG	820
7NZN	ARG	844
7NZN	ALA	845
7NZN	LEU	846
7NZN	THR	847
7NZN	MET	848
7NZN	GLY	849
7NZN	ASP	850
7NZN	LEU	851
7NZN	ILE	852
7NZN	SER	853
7NZN	PHE	854
7NZN	ALA	855
7NZN	TRP	856
7NZN	GLN	857
7NZN	ILE	858
7NZN	SER	859
7NZN	GLN	860
7NZN	GLY	861
7NZN	MET	862
7NZN	GLN	863
7NZN	TYR	864
7NZN	LEU	865
7NZN	ALA	866
7NZN	GLU	867
7NZN	MET	868
7NZN	LYS	869
7NZN	LEU	870
7NZN	VAL	871
7NZN	HIS	872
7NZN	ARG	873
7NZN	ASP	874
7NZN	LEU	875
7NZN	ALA	876
7NZN	ALA	877
7NZN	ARG	878
7NZN	ASN	879
7NZN	ILE	880
7NZN	LEU	881
7NZN	VAL	882
7NZN	ALA	883
7NZN	GLU	884
7NZN	GLY	885
7NZN	ARG	886
7NZN	LYS	887
7NZN	MET	888
7NZN	LYS	889
7NZN	ILE	890
7NZN	SER	891
7NZN	ASP	892
7NZN	PHE	893
7NZN	GLY	894
7NZN	LEU	895
7NZN	SER	896
7NZN	ARG	897
7NZN	ASP	898
7NZN	VAL	899
7NZN	GLU	901
7NZN	GLU	902
7NZN	ASP	903
7NZN	SER	904
7NZN	VAL	906
7NZN	LYS	907
7NZN	ARG	908
7NZN	SER	909
7NZN	GLN	910
7NZN	GLY	911
7NZN	ARG	912
7NZN	ILE	913
7NZN	PRO	914
7NZN	VAL	915
7NZN	LYS	916
7NZN	TRP	917
7NZN	MET	918
7NZN	ALA	919
7NZN	ILE	920
7NZN	GLU	921
7NZN	SER	922
7NZN	LEU	923
7NZN	PHE	924
7NZN	ASP	925
7NZN	HIS	926
7NZN	ILE	927
7NZN	TYR	928
7NZN	THR	929
7NZN	THR	930
7NZN	GLN	931
7NZN	SER	932
7NZN	ASP	933
7NZN	VAL	934
7NZN	TRP	935
7NZN	SER	936
7NZN	PHE	937
7NZN	GLY	938
7NZN	VAL	939
7NZN	LEU	940
7NZN	LEU	941
7NZN	TRP	942
7NZN	GLU	943
7NZN	ILE	944
7NZN	VAL	945
7NZN	THR	946
7NZN	LEU	947
7NZN	GLY	948
7NZN	GLY	949
7NZN	ASN	950
7NZN	PRO	951
7NZN	TYR	952
7NZN	PRO	953
7NZN	GLY	954
7NZN	ILE	955
7NZN	PRO	956
7NZN	PRO	957
7NZN	GLU	958
7NZN	ARG	959
7NZN	LEU	960
7NZN	PHE	961
7NZN	ASN	962
7NZN	LEU	963
7NZN	LEU	964
7NZN	LYS	965
7NZN	THR	966
7NZN	GLY	967
7NZN	HIS	968
7NZN	ARG	969
7NZN	MET	970
7NZN	GLU	971
7NZN	ARG	972
7NZN	PRO	973
7NZN	ASP	974
7NZN	ASN	975
7NZN	CYS	976
7NZN	SER	977
7NZN	GLU	978
7NZN	GLU	979
7NZN	MET	980
7NZN	TYR	981
7NZN	ARG	982
7NZN	LEU	983
7NZN	MET	984
7NZN	LEU	985
7NZN	GLN	986
7NZN	CYS	987
7NZN	TRP	988
7NZN	LYS	989
7NZN	GLN	990
7NZN	GLU	991
7NZN	PRO	992
7NZN	ASP	993
7NZN	LYS	994
7NZN	ARG	995
7NZN	PRO	996
7NZN	VAL	997
7NZN	PHE	998
7NZN	ALA	999
7NZN	ASP	1000
7NZN	ILE	1001
7NZN	SER	1002
7NZN	LYS	1003
7NZN	ASP	1004
7NZN	LEU	1005
7NZN	GLU	1006
7NZN	LYS	1007
7NZN	MET	1008
7NZN	MET	1009
7NZN	VAL	1010
7NZN	LYS	1011
7NZN	ARG	1012
7NZN	ARG	1013

Top

Ramachandran Plot of Kinase Fusion Protein Structure

Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide.

88_CCDC6_RET_ramachandran.png

TKFP_147_CCDC6_RET_ramachandran.png

TKFP_148_CCDC6_RET_ramachandran.png

Top

Virtual Screening Results

Distribution of the average docking score across all approved kinase inhibitors.
Distribution of the number of occurrence across all approved kinase inhibitors.

5'-kinase fusion protein case

3'-kinase fusion protein case

Top

Drug information from DrugBank of the top 20 interacting small molecules.
* The detailed information of individual kinase inhibitors are available in the download page.

Fusion gene name info	Drug	Docking score	Glide g score	Glide energy
88_CCDC6_RET-DOCK_HTVS_1-001	Baricitinib	-7.6255	-7.6255	-38.1601
88_CCDC6_RET-DOCK_HTVS_1-001	Pexidartinib	-7.57448	-7.79128	-38.3854
88_CCDC6_RET-DOCK_HTVS_1-001	Pexidartinib	-7.57448	-7.79128	-38.3854
88_CCDC6_RET-DOCK_HTVS_1-001	Selpercatinib	-7.340660000000001	-7.371160000000001	-49.831
88_CCDC6_RET-DOCK_HTVS_1-001	Selpercatinib	-7.340660000000001	-7.371160000000001	-49.831
88_CCDC6_RET-DOCK_HTVS_1-001	Tepotinib	-6.9319	-6.933	-51.028
88_CCDC6_RET-DOCK_HTVS_1-001	Tofacitinib	-6.776489999999999	-6.78799	-36.3612
88_CCDC6_RET-DOCK_HTVS_1-001	Tofacitinib	-6.776489999999999	-6.78799	-36.3612
88_CCDC6_RET-DOCK_HTVS_1-001	Larotrectinib	-6.7349	-6.7349	-47.8677
88_CCDC6_RET-DOCK_HTVS_1-001	Pexidartinib	-6.6479800000000004	-7.3487800000000005	-38.9859
88_CCDC6_RET-DOCK_HTVS_1-001	Pexidartinib	-6.6479800000000004	-7.3487800000000005	-38.9859
88_CCDC6_RET-DOCK_HTVS_1-001	Tepotinib	-6.53114	-6.53224	-45.4949
88_CCDC6_RET-DOCK_HTVS_1-001	Palbociclib	-6.35348	-6.82298	-42.3282
88_CCDC6_RET-DOCK_HTVS_1-001	Palbociclib	-6.35348	-6.82298	-42.3282
88_CCDC6_RET-DOCK_HTVS_1-001	Palbociclib	-6.35348	-6.82298	-42.3282
88_CCDC6_RET-DOCK_HTVS_1-001	Ripretinib	-6.343459999999999	-6.35046	-47.3352
88_CCDC6_RET-DOCK_HTVS_1-001	Ripretinib	-6.343459999999999	-6.35046	-47.3352
88_CCDC6_RET-DOCK_HTVS_1-001	Midostaurin	-6.3314900000000005	-6.3314900000000005	-44.1353
88_CCDC6_RET-DOCK_HTVS_1-001	Larotrectinib	-6.21535	-6.21535	-43.5149
88_CCDC6_RET-DOCK_HTVS_1-001	Nilotinib	-6.15275	-6.29235	-53.4824

Top

Kinase-Substrate Information of CCDC6_RET

Phosphorylation target of the kinase
(phosphosite, 03-17-2024)

Kinase	Kinase UniProt Acc	Kinase species	Substrate	Substrate UniProt Acc	Substrate phosphorylated residues	Substrate phosphorylated sites (+/-7AA)	Domain
RET	Q15300	human	STAT3	P40763	Y705	DPGsAAPyLktKFIC
RET	Q15300	human	RET	Q15300	Y586	TWIENKLyGRISHAF
RET	P07949	human	RET	P07949	Y981	DNCSEEMyRLMLQCW	PK_Tyr_Ser-Thr
RET	P07949	human	PTK2	Q05397	Y925	DRsNDkVyENVtGLV	Focal_AT
RET	P07949	human	RET	P07949	Y1090	TNTGFPRyPNDSVyA
RET	P07949	human	ATF4	P18848	T107	LGIDDLEtMPDDLLt
RET	P07949	human	PTK2	Q05397	Y577	yMEDstyyKAsKGKL	PK_Tyr_Ser-Thr
RET	P07949	human	ATF4	P18848	T115	MPDDLLttLDDtCDL
RET	P07949	human	MAPK9	P45984	Y185	tNFMMtPyVVtRYYR	Pkinase
RET	P07949	human	RET	P07949	Y1096	RyPNDSVyANWMLSP
RET	P07949	human	MAPK8	P45983	Y185	tsFMMtPyVVtRYYR	Pkinase
RET	P07949	human	PIK3R1	P27986	Y203	PVIPAAVySEMIsLA	RhoGAP
RET	P07949	human	RET	P07949	Y826	SRKVGPGyLGSGGSR	PK_Tyr_Ser-Thr
RET	P07949	human	RET	P07949	Y1015	MMVKRRDyLDLAAST
RET	P07949	human	PDPK1	O15530	Y9	ARTTSQLyDAVPIQS
RET	P07949	human	ATF4	P18848	T114	tMPDDLLttLDDtCD
RET	P07949	human	DOK1	Q99704	Y398	ARVkEEGyELPyNPA
RET	P07949	human	RET	P07949	Y809	LIVEyAKyGSLRGFL	PK_Tyr_Ser-Thr
RET	P07949	human	PTK2	Q05397	Y861	PIGNQHIyQPVGKPD
RET	P07949	human	ATF4	P18848	T119	LLttLDDtCDLFAPL
RET	P07949	human	RET	P07949	Y1029	TPSDSLIyDDGLSEE
RET	P07949	human	RET	P07949	Y687	AQAFPVsysSSGARR
RET	P07949	human	PLCG1	P19174	Y783	EGRNPGFyVEANPMP
RET	P07949	human	MAPK3	P27361	T202	HDHtGFLtEyVAtRW	Pkinase
RET	P07949	human	AFAP1L2	Q8N4X5	Y54	SSSsDEEyIyMNKVt
RET	P07949	human	AKT1	P31749	Y315	tFCGtPEyLAPEVLE	Pkinase
RET	P07949	human	RET	P07949	Y806	PLLLIVEyAKyGSLR	PK_Tyr_Ser-Thr
RET	P07949	human	RET	P07949	Y900	FGLSRDVyEEDsyVK	PK_Tyr_Ser-Thr
RET	P07949	human	MAPK1	P28482	Y187	HtGFLtEyVAtRWyr	Pkinase
RET	P07949	human	RET	P07949	Y905	DVyEEDsyVKRsQGR	PK_Tyr_Ser-Thr
RET	P07949	human	PTK2	Q05397	Y576	RyMEDstyyKAsKGK	PK_Tyr_Ser-Thr
RET	P07949	human	MAPK3	P27361	Y204	HtGFLtEyVAtRWyr	Pkinase
RET	P07949	human	RET	P07949	Y1062	TWIENkLyGMsDPNW
RET	P07949	human	MAPK14	Q16539	Y182	tDDEMtGyVAtRWYR	Pkinase

Biological Network Integration of This Kinase and Substrates
(GeneMANIA website)

Enriched GO biological processes of the phosphorylation target genes of the kinase

Kinase	GOID	GO term	P.adjust
RET	ID	Description	0.00e+00
RET	GO:0071276	cellular response to cadmium ion	8.65e-08
RET	GO:0070849	response to epidermal growth factor	1.02e-07
RET	GO:0038127	ERBB signaling pathway	1.02e-07
RET	GO:0043434	response to peptide hormone	1.02e-07
RET	GO:0048009	insulin-like growth factor receptor signaling pathway	1.02e-07
RET	GO:0046686	response to cadmium ion	1.64e-07
RET	GO:0018105	peptidyl-serine phosphorylation	2.35e-07
RET	GO:0018209	peptidyl-serine modification	2.58e-07
RET	GO:0071375	cellular response to peptide hormone stimulus	2.58e-07
RET	GO:0071248	cellular response to metal ion	7.74e-07
RET	GO:1901653	cellular response to peptide	7.74e-07
RET	GO:0071241	cellular response to inorganic substance	1.52e-06
RET	GO:0007173	epidermal growth factor receptor signaling pathway	1.57e-06
RET	GO:0060416	response to growth hormone	1.79e-06
RET	GO:0034599	cellular response to oxidative stress	2.31e-06
RET	GO:0008286	insulin receptor signaling pathway	2.80e-06
RET	GO:0032868	response to insulin	2.80e-06
RET	GO:0002764	immune response-regulating signaling pathway	3.49e-06
RET	GO:0043491	phosphatidylinositol 3-kinase/protein kinase B signal transduction	3.92e-06
RET	GO:0034198	cellular response to amino acid starvation	4.22e-06
RET	GO:1990928	response to amino acid starvation	5.08e-06
RET	GO:0009411	response to UV	5.10e-06
RET	GO:0038093	Fc receptor signaling pathway	5.10e-06
RET	GO:0062197	cellular response to chemical stress	5.10e-06
RET	GO:0034614	cellular response to reactive oxygen species	5.10e-06
RET	GO:0031663	lipopolysaccharide-mediated signaling pathway	5.49e-06
RET	GO:0061517	macrophage proliferation	5.72e-06
RET	GO:0002768	immune response-regulating cell surface receptor signaling pathway	7.56e-06
RET	GO:0010038	response to metal ion	9.07e-06
RET	GO:0050900	leukocyte migration	1.56e-05
RET	GO:0006979	response to oxidative stress	1.59e-05
RET	GO:0010759	positive regulation of macrophage chemotaxis	1.59e-05
RET	GO:0000302	response to reactive oxygen species	1.59e-05
RET	GO:0032869	cellular response to insulin stimulus	1.59e-05
RET	GO:0071674	mononuclear cell migration	1.59e-05
RET	GO:0051347	positive regulation of transferase activity	1.69e-05
RET	GO:0034764	positive regulation of transmembrane transport	1.90e-05
RET	GO:0071222	cellular response to lipopolysaccharide	2.26e-05
RET	GO:0001503	ossification	2.28e-05
RET	GO:0002685	regulation of leukocyte migration	2.28e-05
RET	GO:0051403	stress-activated MAPK cascade	2.28e-05
RET	GO:0031098	stress-activated protein kinase signaling cascade	2.63e-05
RET	GO:0071219	cellular response to molecule of bacterial origin	2.63e-05
RET	GO:0038095	Fc-epsilon receptor signaling pathway	2.75e-05
RET	GO:0060396	growth hormone receptor signaling pathway	2.75e-05
RET	GO:0018107	peptidyl-threonine phosphorylation	2.76e-05
RET	GO:0048863	stem cell differentiation	2.76e-05
RET	GO:0002757	immune response-activating signaling pathway	2.76e-05
RET	GO:0071378	cellular response to growth hormone stimulus	2.79e-05

Top

Related Drugs to CCDC6_RET

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene	Tgene	Drug	Source	PMID
CCDC6	RET	Pembrolizumab	PubMed	33845248

Distribution of the number of studies mentioning CCDC6-RET and kinase inhibitors the PubMed Abstract (04-01-2024)

Fusion gene - drug pair 1	Fusion gene - drug pair 2	PMID	Publication date	DOI	Study title
CCDC6-RET AND Sorafenib	CCDC6-RET AND Alectinib	31226468	2019-9	10.1016/j.bioorg.2019.103052	Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
CCDC6-RET AND Crizotinib	CCDC6-RET AND Lorlatinib	35815322	2022-7	10.1016/j.jtocrr.2022.100347	A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
CCDC6-RET AND Vandetanib		23578175	2020-02-08	10.32388/6b4jx3	Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
CCDC6-RET AND Cabozantinib		32914006	2019-12	10.1200/po.18.00295	Use of Cabozantinib in a Patient With EGFR-Mutated Non-Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion.
CCDC6-RET AND Nintedanib		29263244	2017-12-20	10.1124/jpet.117.244129	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
CCDC6-RET AND Alectinib	KIF5B-RET AND Alectinib	31698333	2020-1	10.1016/j.lungcan.2019.10.020	Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
CCDC6-RET AND Alectinib	NCOA4-RET AND Alectinib	29088743	2017-05-16	10.18632/oncotarget.17900	In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.
CCDC6-RET AND Lenvatinib	KIF5B-RET AND Lenvatinib	31710864	2019-12	10.1016/j.lungcan.2019.09.011	A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
CCDC6-RET AND Lenvatinib	KIF5B-RET AND Lenvatinib	23856031	2013-10	10.1016/j.canlet.2013.07.007	Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
CCDC6-RET AND Osimertinib	STRN-ALK AND Selpercatinib	36996322	2023-03-30	10.1158/1078-0432.ccr-22-2189	"Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers."
CCDC6-RET AND Osimertinib		36129569	2022-09-21	10.1007/s11523-022-00915-9	Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
CCDC6-RET AND Osimertinib	STRN-ALK AND Osimertinib	35462930	2022-04-06	10.3389/fphar.2022.838247	Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
CCDC6-RET AND Osimertinib	CCDC6-RET AND Selpercatinib	33641722	2021-3	10.1016/j.jtho.2020.09.020	Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
CCDC6-RET AND Osimertinib		30257958	2018-12-01	10.1158/2159-8290.cd-18-1022	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
CCDC6-RET AND Pralsetinib		37141396	2023-05-04	10.1093/oncolo/oyad115	Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation.
CCDC6-RET AND Pralsetinib		36327463	2022-11-11	10.1097/rlu.0000000000004475	"Reversing ""Flip-Flop"" Phenomenon of 131 I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib."
CCDC6-RET AND Pralsetinib		35751411	2022-6	10.1177/03000605221105368	Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report.
CCDC6-RET AND Pralsetinib		35571397	2022-4	10.21037/atm-22-1237	Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report.
CCDC6-RET AND Selpercatinib		38378752	2024-02-20	10.1038/s41698-024-00536-7	Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.
CCDC6-RET AND Selpercatinib		36825106	2022-09-27	10.1159/000526030	Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.
CCDC6-RET AND Selpercatinib		33161056	2021-2	10.1016/j.annonc.2020.10.599	Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Top

Related Diseases to CCDC6_RET

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene	Tgene	Disease	Source	PMID
CCDC6	RET	Pd-L1+ Lung Adenocarcinoma	PubMed	33845248
CCDC6	RET	Ung Adenocarcinoma	MyCancerGenome
CCDC6	RET	Thyroid Gland Papillary Carcinoma	MyCancerGenome
CCDC6	RET	Poorly Differentiated Thyroid Gland Carcinoma	MyCancerGenome
CCDC6	RET	Breast Invasive Ductal Carcinoma	MyCancerGenome
CCDC6	RET	Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	MyCancerGenome

Related diseases from the literature mentioned this fusion gene and drug.
(PubMed, 04-01-2024)

MeSH ID	MeSH term
D000077273	Thyroid Cancer, Papillary

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	CCDC6	C0238463	Papillary thyroid carcinoma	2	CTD_human;ORPHANET
Tgene	RET	C1833921	Familial medullary thyroid carcinoma	23	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene	RET	C3888239	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1	16	GENOMICS_ENGLAND;UNIPROT
Tgene	RET	C0025268	Multiple Endocrine Neoplasia Type 2a	15	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene	RET	C1708353	Hereditary Paraganglioma-Pheochromocytoma Syndrome	12	CLINGEN
Tgene	RET	C0025269	Multiple Endocrine Neoplasia Type 2b	10	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene	RET	C0238463	Papillary thyroid carcinoma	3	CTD_human;ORPHANET
Tgene	RET	C1275808	Congenital central hypoventilation	3	CTD_human;GENOMICS_ENGLAND;UNIPROT
Tgene	RET	C1859049	CCHS WITH HIRSCHSPRUNG DISEASE	3	CTD_human;ORPHANET
Tgene	RET	C0009402	Colorectal Carcinoma	2	CTD_human;UNIPROT
Tgene	RET	C0009404	Colorectal Neoplasms	2	CTD_human
Tgene	RET	C0019569	Hirschsprung Disease	2	CTD_human
Tgene	RET	C0027662	Multiple Endocrine Neoplasia	2	CTD_human;GENOMICS_ENGLAND
Tgene	RET	C0085758	Aganglionosis, Colonic	2	CTD_human
Tgene	RET	C0266294	Unilateral agenesis of kidney	2	ORPHANET
Tgene	RET	C1257840	Aganglionosis, Rectosigmoid Colon	2	CTD_human
Tgene	RET	C3661523	Congenital Intestinal Aganglionosis	2	CTD_human

Top

Clinical Trials of the Found Drugs/Small Molecules

Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024)

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene	Kinase Inhibitor	NCT ID	Study Status	Phases	Disease	# Enrolment	Date
CCDC6-RET	Pralsetinib	NCT04222972	Active, not recruiting	Phase 3	RET-fusion Non Small Cell Lung Cancer	223	June 30, 2025
CCDC6-RET	Pralsetinib	NCT03037385	Completed	Phase 1	RET-altered Non Small Cell Lung Cancer	589	March 21, 2024
CCDC6-RET	Alectinib	NCT05525858	Recruiting		Solid Tumor	1000	September 2025
CCDC6-RET	Pralsetinib	NCT05525858	Recruiting		Solid Tumor	1000	September 2025
CCDC6-RET	Selpercatinib	NCT03157128	Recruiting	Phase 1	Non-Small Cell Lung Cancer	875	February 28, 2026
CCDC6-RET	Selpercatinib	NCT03899792	Recruiting	Phase 1	Medullary Thyroid Cancer	50	May 31, 2029